Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir

Journal of Acquired Immune Deficiency Syndromes

Volumn 45, Issue 2, 2007, Pages 201-205

  Pham, Paul A ^a,d   Flexner, Charles ^a   Parsons, Teresa ^a   Vasist, Lakshmi ^b   Fuchs, Edward ^a   Carson, Kathryn ^a   Agarwala, Sangeeta ^c   Barditch Crovo, Patricia ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d NONE   (United States)

Author keywords

Atazanavir; Drug interaction; Lopinavir; Pharmacokinetics; Ritonavir

Indexed keywords

ATAZANAVIR; LOPINAVIR PLUS RITONAVIR; RITONAVIR;

ADULT; ANALYTICAL PARAMETERS; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLATULENCE; GEOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INCREASED APPETITE; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; STEADY STATE; STUDENT T TEST; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; PYRIMIDINONES; RITONAVIR;

EID: 34249890243     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318050d632     Document Type: Article

References (15)

1. Duvivier C, Peytavin G, Ait-Mohand H, et al. Dual boosted atazanavir/lopinavir/ritonavir containing regimen in HIV-1 infected pretreated patients: plasma trough concentration and efficacy results [abstract WePe3.2C10]. Presented at: 3rd International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment, July 24-27, 2005.
2. Chan-Tack KM, Qaqish RB, Fantry LE, et al. Successful treatment with lopinavir/ritonavir (LPV/r) and atazanavir (ATV) combination therapy in protease inhibitor (PI)-naïve and PI-experienced HIV-infected patients [abstract 796]. Presented at: 43rd Annual Meeting of the Infectious Disease Society of America (IDSA); 2005; San Francisco.
3. Ballinger J, Swaden L, Bhaganis, et al. Double-boosted protease treatment using atazanavir and lopinavir/ritonavir. Presented at: 11th Annual Conference of the British HIV Association.
4. Ribera E, Azuaje C, Lopez, RM, et al. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. AIDS 2006;20:1131-1139.
5. Langman P, Zilly M, Winzer R, et al. Efficacy and safety of ATV in combination with LPV/r [abstract 56]. Presented at: International Workshop on Clinical Pharmacology of HIV Therapy; 2005; Quebec.
6. Chandler B, Almond L, Ford J, et al. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro. J Acquir Immune Defic Syndr. 2003;33:551-556.
7. Bristol-Myers Squibb Company. Reyataz [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2003.
8. Perloff ES, Duan SX, Skolnik PR, et al. Atazanavir: effects on P-glycoprotein transport and CYP3A4 metabolism in vitro. Drug Metab Dispos. 2005;33:764-770.
9. Lamotte C, Peytavin G, Farinotti R. Determination of nelfinavir, a potent HIV protease inhibitor, and its active metabolite M8 in human plasma by high-performance liquid chromatography with photodiode-array detection. J Chromatogr B Biomed Sci Appl. 1999;735:159-170.
10. von Hentig N, Haberl A, Mueller A, et al. Atazanavir (ATV) co-administration on the pharmacokinetics (PK) of either saquinavir (SQV), lopinavir (LPV) or fosamprenavir (FOSAPV) when combined in ritonavir (RTV)-boosted double protease inhibitor (PI) therapy regimen [abstract PS6/5]. Presented at: 10th European AIDS Conference; 2005; Dublin.
11. von Hentig N, Carlebach A, Rottman C, et al. Effect of the coadministration of either saquinavir (SQV), lopinavir (LPV) or fosamprenavir (FOSAPV) on atazanavir (ATV) plasma exposure in boosted double protease inhibitor (PI) therapy regimens [abstract PS6/6]. Presented at: 10th European AIDS Conference; 2005; Dublin.
12. Winston A, Bloch M, Carr A, et al. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy. J Antimicrob Chemother. 2005;56:380-387.
13. Colombo S, Buclin T, Franc C, et al. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures. Antivir Ther. 2006;11:53-62.
14. Bertz R, Li J, Rode R, et al. Adherence in combination with lopinavir inhibitory quotient (IQ) and number of active antiretrovirals (ARVs) predicts virologic response in highly ARV-experienced patients receiving high-dose lopinavir/ritonavir (LPV/r) [abstract P91]. Presented at: Seventh International Congress on Drug Therapy in HIV Infection; 2004; Glasgow.
15. O'Mara E, Mummaneni V, Bifano M, et al. Steady-state pharmacokinetic interaction study between BMS-232632 and ritonavir in healthy subjects [abstract 740]. Presented at: Eighth Conference on Retroviruses and Opportunistic Infections; 2001; Chicago.